Biotechnology: German Industry Beefs Up

Schering’s commitment to biotechnology in the early 1990s was a landmark decision for the company, says Dr. Guiseppe Vita, who is stepping down as chairman of the Berlin-based company. The result of that commitment was Betaferon (interferon beta-Ib), one of the first biotech products on the market in Germany. It is now Schering’s biggest product and one of the top ten best selling biotech therapies in the world.

Related Content:

Pharmaceutical Executive-06-01-2001

Industry Under Investigation

Covering the Bases

Emotion - The New Brand Integrator